Trastuzumab and pertuzumab after surgery for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new combination of two HER2-targeted drugs (trastuzumab and pertuzumab) given after surgery for HER2-positive breast cancer. It looks at whether this combination can help reduce the risk of cancer coming back in people who still had some cancer left after neoadjuvant therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 18 and 75.
- You were diagnosed with HER2-positive breast cancer and had surgery after neoadjuvant therapy (treatment before surgery).
- After surgery, there was still some cancer left in the breast or lymph nodes.
- You have already completed at least 8 cycles (about 24 weeks) of treatment with trastuzumab and pertuzumab after surgery.
- Your last dose of trastuzumab was within the past year.
- You must be in generally good health and have normal heart, liver, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.